Home/Filings/4/0000899243-20-018121
4//SEC Filing

Wallace Owen B. 4

Accession 0000899243-20-018121

CIK 0001680581other

Filed

Jun 30, 8:00 PM ET

Accepted

Jul 1, 4:39 PM ET

Size

8.8 KB

Accession

0000899243-20-018121

Insider Transaction Report

Form 4
Period: 2020-06-30
Wallace Owen B.
Chief Scientific Officer
Transactions
  • Exercise/Conversion

    Stock Option (right to buy)

    2020-06-3014184,893 total
    Exercise: $7.84Exp: 2029-01-21Common Stock (141 underlying)
  • Exercise/Conversion

    Common Stock

    2020-06-30$7.84/sh+141$1,105127,229 total
  • Sale

    Common Stock

    2020-06-30$20.00/sh141$2,820127,088 total
Footnotes (2)
  • [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019.
  • [F2]The shares underlying the option are scheduled to vest in equal quarterly installments from January 1, 2019 through December 31, 2022.

Issuer

Fulcrum Therapeutics, Inc.

CIK 0001680581

Entity typeother

Related Parties

1
  • filerCIK 0001778843

Filing Metadata

Form type
4
Filed
Jun 30, 8:00 PM ET
Accepted
Jul 1, 4:39 PM ET
Size
8.8 KB